Literature DB >> 26418335

Temporal cAMP Signaling Selectivity by Natural and Synthetic MC4R Agonists.

Brent M Molden1, Kimberly A Cooney1, Kirk West1, Lex H T Van Der Ploeg1, Giulia Baldini1.   

Abstract

The melanocortin-4 receptor (MC4R) is a G protein-coupled receptor expressed in the brain, where it controls energy balance through pathways including α-melanocyte-stimulating hormone (α-MSH)-dependent signaling. We have reported that the MC4R can exist in an active conformation that signals constitutively by increasing cAMP levels in the absence of receptor desensitization. We asked whether synthetic MC4R agonists differ in their ability to increase intracellular cAMP over time in Neuro2A cells expressing endogenous MC4R and exogenous, epitope-tagged hemagglutinin-MC4R-green fluorescent protein. By analyzing intracellular cAMP in a temporally resolved Förster resonance energy transfer assay, we show that withdrawal of α-MSH leads to a quick reversal of cAMP induction. By contrast, the synthetic agonist melanotan II (MTII) induces a cAMP signal that persists for at least 1 hour after removal of MTII from the medium and cannot be antagonized by agouti related protein. Similarly, in mHypoE-42 immortalized hypothalamic neurons, MTII, but not α-MSH, induced persistent AMP kinase signal, which occurs downstream of increased cAMP. By using a fluorescence recovery after photobleaching assay, it appears that the receptor exposed to MTII continues to signal after being internalized. Similar to MTII, the synthetic MC4R agonists, THIQ and BIM-22511, but not LY2112688, induced prolonged cAMP signaling after agonist withdrawal. However, agonist-exposed MC4R desensitized to the same extent, regardless of the ligand used and regardless of differences in receptor intracellular retention kinetics. In conclusion, α-MSH and LY2112688, when compared with MTII, THIQ, and BIM-22511, vary in the duration of the acute cAMP response, showing distinct temporal signaling selectivity, possibly linked to specific cell compartments from which cAMP signals may originate.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26418335      PMCID: PMC4627605          DOI: 10.1210/me.2015-1071

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  53 in total

1.  Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein.

Authors:  M M Ollmann; B D Wilson; Y K Yang; J A Kerns; Y Chen; I Gantz; G S Barsh
Journal:  Science       Date:  1997-10-03       Impact factor: 47.728

2.  Agonist-selective, receptor-specific interaction of human P2Y receptors with beta-arrestin-1 and -2.

Authors:  Carsten Hoffmann; Nicole Ziegler; Susanne Reiner; Cornelius Krasel; Martin J Lohse
Journal:  J Biol Chem       Date:  2008-08-14       Impact factor: 5.157

3.  Role of dynamin in the formation of transport vesicles from the trans-Golgi network.

Authors:  S M Jones; K E Howell; J R Henley; H Cao; M A McNiven
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

4.  Effects of recombinant agouti-signaling protein on melanocortin action.

Authors:  Y K Yang; M M Ollmann; B D Wilson; C Dickinson; T Yamada; G S Barsh; I Gantz
Journal:  Mol Endocrinol       Date:  1997-03

5.  Design of potent linear alpha-melanotropin 4-10 analogues modified in positions 5 and 10.

Authors:  F Al-Obeidi; V J Hruby; A M Castrucci; M E Hadley
Journal:  J Med Chem       Date:  1989-01       Impact factor: 7.446

6.  Morphine activates opioid receptors without causing their rapid internalization.

Authors:  D E Keith; S R Murray; P A Zaki; P C Chu; D V Lissin; L Kang; C J Evans; M von Zastrow
Journal:  J Biol Chem       Date:  1996-08-09       Impact factor: 5.157

7.  Essential role for G protein-coupled receptor endocytosis in the activation of mitogen-activated protein kinase.

Authors:  Y Daaka; L M Luttrell; S Ahn; G J Della Rocca; S S Ferguson; M G Caron; R J Lefkowitz
Journal:  J Biol Chem       Date:  1998-01-09       Impact factor: 5.157

8.  Mu opioid receptor phosphorylation, desensitization, and ligand efficacy.

Authors:  Y Yu; L Zhang; X Yin; H Sun; G R Uhl; J B Wang
Journal:  J Biol Chem       Date:  1997-11-14       Impact factor: 5.157

9.  Characterizations of the unusual dissociation properties of melanotropin peptides from the melanocortin receptor, hMC1R.

Authors:  C Haskell-Luevano; H Miwa; C Dickinson; M E Hadley; V J Hruby; T Yamada; I Gantz
Journal:  J Med Chem       Date:  1996-01-19       Impact factor: 7.446

10.  Preferential antagonism of the interactions of the integrin alpha IIb beta 3 with immobilized glycoprotein ligands by snake-venom RGD (Arg-Gly-Asp) proteins. Evidence supporting a functional role for the amino acid residues flanking the tripeptide RGD in determining the inhibitory properties of snake-venom RGD proteins.

Authors:  X Lu; J A Williams; J J Deadman; G P Salmon; V V Kakkar; J M Wilkinson; D Baruch; K S Authi; S Rahman
Journal:  Biochem J       Date:  1994-12-15       Impact factor: 3.857

View more
  10 in total

1.  Structural Insights into Selective Ligand-Receptor Interactions Leading to Receptor Inactivation Utilizing Selective Melanocortin 3 Receptor Antagonists.

Authors:  Minying Cai; Udaya Kiran Marelli; Blake Mertz; Johannes G Beck; Florian Opperer; Florian Rechenmacher; Horst Kessler; Victor J Hruby
Journal:  Biochemistry       Date:  2017-08-01       Impact factor: 3.162

Review 2.  The melanocortin pathway and control of appetite-progress and therapeutic implications.

Authors:  Giulia Baldini; Kevin D Phelan
Journal:  J Endocrinol       Date:  2019-04-01       Impact factor: 4.286

3.  Lipid stress inhibits endocytosis of melanocortin-4 receptor from modified clathrin-enriched sites and impairs receptor desensitization.

Authors:  Kimberly A Cooney; Brent M Molden; Nicholas S Kowalczyk; Susan Russell; Giulia Baldini
Journal:  J Biol Chem       Date:  2017-09-06       Impact factor: 5.157

4.  Activation of the central melanocortin system chronically reduces body mass without the necessity of long-term caloric restriction.

Authors:  I Côté; Y Sakarya; N Kirichenko; D Morgan; C S Carter; N Tümer; P J Scarpace
Journal:  Can J Physiol Pharmacol       Date:  2016-10-19       Impact factor: 2.273

5.  Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.

Authors:  Tinh-Hai Collet; Béatrice Dubern; Jacek Mokrosinski; Hillori Connors; Julia M Keogh; Edson Mendes de Oliveira; Elana Henning; Christine Poitou-Bernert; Jean-Michel Oppert; Patrick Tounian; Florence Marchelli; Rohia Alili; Johanne Le Beyec; Dominique Pépin; Jean-Marc Lacorte; Andrew Gottesdiener; Rebecca Bounds; Shubh Sharma; Cathy Folster; Bart Henderson; Stephen O'Rahilly; Elizabeth Stoner; Keith Gottesdiener; Brandon L Panaro; Roger D Cone; Karine Clément; I Sadaf Farooqi; Lex H T Van der Ploeg
Journal:  Mol Metab       Date:  2017-07-08       Impact factor: 7.422

Review 6.  Current Mechanistic and Pharmacodynamic Understanding of Melanocortin-4 Receptor Activation.

Authors:  Shubh Sharma; Alastair S Garfield; Bhavik Shah; Patrick Kleyn; Ilia Ichetovkin; Ida Hatoum Moeller; William R Mowrey; Lex H T Van der Ploeg
Journal:  Molecules       Date:  2019-05-16       Impact factor: 4.411

7.  Selective Survival of Sim1/MC4R Neurons in Diet-Induced Obesity.

Authors:  Eugene Nyamugenda; Haven Griffin; Susan Russell; Kimberly A Cooney; Nicholas S Kowalczyk; Ishrar Islam; Kevin D Phelan; Giulia Baldini
Journal:  iScience       Date:  2020-05-01

Review 8.  The Role of Melanocortin Plasticity in Pain-Related Outcomes After Alcohol Exposure.

Authors:  Nathan Sharfman; Nicholas W Gilpin
Journal:  Front Psychiatry       Date:  2021-11-04       Impact factor: 4.157

9.  Regulation of energy rheostasis by the melanocortin-3 receptor.

Authors:  Masoud Ghamari-Langroudi; Isin Cakir; Rachel N Lippert; Patrick Sweeney; Michael J Litt; Kate L J Ellacott; Roger D Cone
Journal:  Sci Adv       Date:  2018-08-22       Impact factor: 14.136

10.  Common Genetic Variation in MC4R Does Not Affect Atherosclerotic Plaque Phenotypes and Cardiovascular Disease Outcomes.

Authors:  Lisanne L Blauw; Raymond Noordam; Sander W van der Laan; Stella Trompet; Sander Kooijman; Diana van Heemst; Johan Wouter Jukema; Jessica van Setten; Gert J de Borst; Anne Tybjærg-Hansen; Gerard Pasterkamp; Jimmy F P Berbée; Patrick C N Rensen
Journal:  J Clin Med       Date:  2021-03-01       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.